Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

Key Points

• Analysts rate Whitehawk Therapeutics “Moderate Buy”: seven of eight covering brokerages recommend buying the stock, while one rates it a sell. The average 12-month price target is $8.33, with recent targets ranging from $9 to $10.
• Institutional investors own 52.08% of WHWK, with Montanova Capital increasing its stake and BlackRock and ADAR1 Capital Management establishing new positions during the second quarter.
• Shares opened at $3.41, down 5.5%, and remain below their 50-day and 200-day moving averages. The company reported a quarterly loss of $0.20 per share, better than the expected $0.30 loss.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.33.

WHWK has been the subject of several recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Wall Street Zen raised shares of Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Leerink Partners initiated coverage on Whitehawk Therapeutics in a research note on Monday, July 13th. They issued an "outperform" rating and a $9.00 price target for the company. B. Riley Financial assumed coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a "buy" rating and a $10.00 price objective for the company. Finally, Stifel Nicolaus started coverage on Whitehawk Therapeutics in a research note on Wednesday, September 30th. They set a "buy" rating and a $9.00 price objective on the stock.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several large investors have recently added to or reduced their stakes in WHWK. Montanova Capital LLC grew its stake in shares of Whitehawk Therapeutics by 16.2% in the second quarter. Montanova Capital LLC now owns 4,300,000 shares of the company's stock worth $19,694,000 after purchasing an additional 600,000 shares in the last quarter. BlackRock Inc. acquired a new position in Whitehawk Therapeutics during the 2nd quarter valued at about $8,807,000. ADAR1 Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics in the 2nd quarter worth approximately $6,144,000. Eversept Partners LP boosted its holdings in shares of Whitehawk Therapeutics by 17.9% in the first quarter. Eversept Partners LP now owns 306,800 shares of the company's stock valued at $1,058,000 after acquiring an additional 46,541 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Whitehawk Therapeutics during the second quarter valued at approximately $378,000. 52.08% of the stock is currently owned by institutional investors.

Whitehawk Therapeutics Stock Down 5.5%

Shares of WHWK opened at $3.41 on Thursday. The firm has a market cap of $194.40 million, a price-to-earnings ratio of -3.04 and a beta of 0.92. The business's 50 day moving average is $4.29 and its two-hundred day moving average is $4.13. Whitehawk Therapeutics has a 52-week low of $1.87 and a 52-week high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. On average, equities analysts expect that Whitehawk Therapeutics will post -1.07 earnings per share for the current fiscal year.

Whitehawk Therapeutics Company Profile

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company's work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue.

Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization.

Publicly available information about the company's specific pipeline, geographic operations, and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.